GICS Sector : Healthcare
Senti Biosciences, Inc.operates as a gene circuit company.The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
Dec -04
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
Nov -13
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
Nov -03
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
Oct -16
Senti Bio to Present at BioJapan
Oct -06
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
Sep -18
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sep -02
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Aug -14
Senti Biosciences' next-generation cell and gene therapies are driven by increasing demand for personalized medicine, advancements in gene editing technologies like CRISPR, and growing investments in regenerative medicine. Additionally, the company's proprietary gene circuit technology and strong partnerships with pharmaceutical companies contribute to its 3.0 growth rate.
A suite of tools and services for the design, construction, and optimization of gene circuits for various applications
Personalized cancer therapies using gene circuits to selectively kill cancer cells
Gene circuits for the regulation of gene expression to treat genetic disorders
A platform for the design, construction, and testing of genetic circuits
Gene-modified cells for the treatment of various diseases, including cancer and genetic disorders
Senti Biosciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.
Senti Biosciences, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Senti Biosciences, Inc. relies on a few key suppliers for critical components, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Senti Biosciences, Inc.
The biotechnology industry is highly competitive, with many established companies competing for market share. Senti Biosciences, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
| Value | |
|---|---|
| Debt Weight | 36.02% |
| Debt Cost | 3.95% |
| Equity Weight | 63.98% |
| Equity Cost | 18.35% |
| WACC | 13.16% |
| Leverage | 56.29% |
Value: 7.4
Growth: 8.0
Quality: 7.0
Yield: 0.0
Momentum: 10.0
Volatility: 1.0
1-Year Total Return ->
Value: 2.2
Growth: 7.1
Quality: 4.6
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 9.6
Growth: 5.4
Quality: 5.2
Yield: 0.0
Momentum: 0.5
Volatility: 2.0
1-Year Total Return ->
Value: 9.0
Growth: 6.2
Quality: 6.1
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 8.8
Growth: 3.4
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 7.0
Growth: 2.9
Quality: 2.9
Yield: 0.0
Momentum: 2.0
Volatility: 0.3
1-Year Total Return ->